News
Chinese Biotech Stocks Surge After 3SBio's $6 Billion Licensing Deal With Pfizer -- Update
Pfizer's US$6 billion licensing deal with 3SBio has boosted market sentiment on Chinese biotech and pharmaceutical companies, sending shares in the sector higher. 3SBio's shares surged 32% to 19.18 Hong Kong dollars,
China continues to be a source of innovation as Pfizer strikes biggest pact yet; HHS provides more info on Trump’s Most ...
Moscicki previously served as the deputy center director for science operations at the FDA’s Center for Drug Evaluation and ...
Pfizer (NYSE:PFE) indicated plans to explore acquisitions or partnerships to add cardiometabolic assets, including weight loss therapies, to the pipeline, following a major trial setback this ...
An eight-member panel voted unanimously against wider use of Pfizer’s Talzenna in advanced prostate cancer. Elsewhere, U.K.
Pfizer-backed CellCentric has secured $120 million in series C funds as the British biotech prepares to take its multiple ...
Some five years into a pneumococcal vaccine patent dispute in South Korea, SK Bioscience has emerged victorious over Pfizer.
Talzenna is currently approved in combination with Xtandi (enzalutamide) for individuals with castration-resistant prostate ...
The House Judiciary Committee revealed Thursday that Pfizer’s former Global Head of Vaccines Research and Development, Dr. Philip Dormitzer, may have “conspired to withhold public health infor ...
Shares of Moderna surged to lead S&P 500 gainers Tuesday after the Food and Drug Administration issued new guidance for COVID ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback